Gleamer
AI second reader for X-rays: FDA-cleared fracture detection that flags regions for radiologists.
About
Gleamer builds AI companions for standard X-ray imaging, led by BoneView, which detects and localizes bone fractures and highlights them with bounding boxes so radiologists can prioritize reading. BoneView is FDA-cleared as a CADe/CADx device and CE MDR class IIa certified in Europe, including use in children over two, which the company says makes it the first pediatric-cleared AI fracture tool in the US. In a multi-center study led by Boston University, the company reports BoneView improved fracture-detection sensitivity by 10.4% with standalone AUC of 0.97, supported by nearly 25 peer-reviewed publications.
The French company says BoneView has analyzed over 3 million images and is used by 3,500+ radiologists and emergency physicians across 300+ institutions in 13-16 countries. Its distribution runs through partners including Aidoc, Fujifilm, and Blackford, and Konica Minolta added BoneView to its DR portfolio in a September 2026 partnership. It is strictly a decision-support tool: it flags regions of interest and the radiologist makes the final call.
What it can do
- BoneView fracture detection and localization on X-rays
- Bounding-box regions of interest with confidence levels
- FDA-cleared CADe/CADx, CE MDR class IIa (including pediatric use)
- ChestView chest imaging AI
- MSK measurements and pediatric bone age assessment
- Integration into existing radiology reading environments
- Distribution via Aidoc, Fujifilm, Blackford, and Konica Minolta
Setup
- Gleamer is sold to hospitals and imaging centers, not individuals.
- Contact Gleamer or a distribution partner (Aidoc, Fujifilm, Blackford, Konica Minolta) for a demo.
- BoneView integrates into the radiologist's existing reading environment (PACS/RIS).
- Radiologists review flagged regions and make the final diagnosis.
Prerequisites
Institutional contract; radiology practice with PACS/RIS infrastructure.
Use cases
Works with
Trust score — 8/10
Scored 8/10 (verified tier, metrics-v1). Evidence: FDA clearance as CADe/CADx plus CE MDR IIa (Applied Radiology, BioSpace); multi-center Boston University study with 10.4% sensitivity improvement and 0.97 standalone AUC (Applied Radiology, Sep 2026); ~25 peer-reviewed publications; partnerships with Aidoc, Fujifilm, and Konica Minolta (PR Newswire, Applied Radiology). Strengths: dual regulatory clearance, published clinical evidence, broad enterprise distribution. Docked for: (1) still a radiologist's second reader, not autonomous diagnosis; (2) deployment figures are company-reported. License: proprietary.
How the trust score is built
Full methodology →- Adoption · stars/downloads, log-scaled vs peers
- 8.0/10
- Maintenance · recency, releases, issue load
- 8.0/10
- Openness · license + docs
- 8.0/10
- Manual review · sanity read + red-flag check
- 8.0/10
- · FDA clearance as CADe/CADx plus CE MDR class IIa (Applied Radiology, BioSpace)
- · Multi-center Boston University study: 10.4% sensitivity improvement, 0.97 standalone AUC (Applied Radiology, Sep 2026)
- · ~25 peer-reviewed publications claimed
- · Partnerships with Aidoc, Fujifilm, Blackford, Konica Minolta (PR Newswire, Applied Radiology)
- · 3M+ images analyzed, 3,500+ radiologists claimed (company-reported)
Sources
Every fact above was checked against these sources. Where a claim comes from the provider and couldn't be independently verified, the text says so.